Molecular Mechanism Regulating Regeneration of Spinal Nerves Identified
|
By LabMedica International staff writers Posted on 29 Mar 2016 |

Image: A confocal micrograph of the lesion core following spinal cord injury. Nuclear EdU (red) shows the presence of newly differentiated cells which produce Schwann cell myelin (green). These peripheral-like Schwann cells remyelinate central axons in the injured spinal cord and are important for spontaneous repair and functional recovery after spinal cord injury (Photo courtesy of King\'s College London).
The protein neuregulin-1 was found to regulate the repair mechanism that attempts to restore lost myelin following spinal cord injury.
Following traumatic spinal cord injury, acute demyelination of spinal axons is followed by a period of spontaneous remyelination. However, this endogenous repair response is incomplete and may account for the chronic loss of function demonstrated by surviving axons. Spontaneous remyelination is largely mediated by Schwann cells, where demyelinated central axons, particularly in the dorsal columns, become associated with peripheral myelin. The molecular control mechanism, functional role, and origin of these central remyelinating Schwann cells are currently unknown.
The growth factor neuregulin-1 (Nrg1, encoded by the NRG1 gene) is a key signaling factor controlling myelination in the peripheral nervous system, via signaling through ErbB tyrosine kinase receptors. The neuregulins are a family of four structurally related proteins that are part of the EGF (epidermal growth factor) family of proteins, which have been shown to have diverse functions in the development of the nervous system.
Investigators at King's College London (United Kingdom) and the University of Oxford (United Kingdom) examined whether Nrg1 was required for Schwann cell-mediated remyelination of central dorsal column axons and whether removal of Nrg1 would influence the degree of spontaneous remyelination and functional recovery following spinal cord injury.
They reported in the March 17, 2016, online edition of the journal Brain that Nrg1 signaling mediated an endogenous regenerative event in which Schwann cells remyelinated denuded central axons after traumatic spinal cord injury and that Nrg1 was an important mediator of spontaneous functional repair after spinal cord injury. In mice lacking the NRG1 gene, spontaneous myelin repair was completely prevented and spinal nerve fibers remained demyelinated. Furthermore, mice without NRG1 showed worse outcomes after spinal cord injury compared to mice with the gene intact, particularly in walking, balance, and coordinated movements.
Senior author Dr. Elizabeth Bradbury, professor of regenerative medicine and neuroplasticity at King's College London, said, "Spinal cord injury could happen to anyone, at any time. In an instant your life could change and you could lose all feeling and function below the level of the injury. Existing treatments are largely ineffective, so there is a pressing need for new regenerative therapies to repair tissue damage and restore function after spinal cord injury."
"These new findings advance our understanding of the molecular mechanisms which may orchestrate the body's remarkable capacity for natural repair," said Dr. Bradbury.
"By enhancing this spontaneous response, we may be able to significantly improve spinal cord function after injury. Our research also has wider implications for other disorders of the central nervous system which share this demyelinating pathology, such as multiple sclerosis."
Related Links:
King's College London
University of Oxford
Following traumatic spinal cord injury, acute demyelination of spinal axons is followed by a period of spontaneous remyelination. However, this endogenous repair response is incomplete and may account for the chronic loss of function demonstrated by surviving axons. Spontaneous remyelination is largely mediated by Schwann cells, where demyelinated central axons, particularly in the dorsal columns, become associated with peripheral myelin. The molecular control mechanism, functional role, and origin of these central remyelinating Schwann cells are currently unknown.
The growth factor neuregulin-1 (Nrg1, encoded by the NRG1 gene) is a key signaling factor controlling myelination in the peripheral nervous system, via signaling through ErbB tyrosine kinase receptors. The neuregulins are a family of four structurally related proteins that are part of the EGF (epidermal growth factor) family of proteins, which have been shown to have diverse functions in the development of the nervous system.
Investigators at King's College London (United Kingdom) and the University of Oxford (United Kingdom) examined whether Nrg1 was required for Schwann cell-mediated remyelination of central dorsal column axons and whether removal of Nrg1 would influence the degree of spontaneous remyelination and functional recovery following spinal cord injury.
They reported in the March 17, 2016, online edition of the journal Brain that Nrg1 signaling mediated an endogenous regenerative event in which Schwann cells remyelinated denuded central axons after traumatic spinal cord injury and that Nrg1 was an important mediator of spontaneous functional repair after spinal cord injury. In mice lacking the NRG1 gene, spontaneous myelin repair was completely prevented and spinal nerve fibers remained demyelinated. Furthermore, mice without NRG1 showed worse outcomes after spinal cord injury compared to mice with the gene intact, particularly in walking, balance, and coordinated movements.
Senior author Dr. Elizabeth Bradbury, professor of regenerative medicine and neuroplasticity at King's College London, said, "Spinal cord injury could happen to anyone, at any time. In an instant your life could change and you could lose all feeling and function below the level of the injury. Existing treatments are largely ineffective, so there is a pressing need for new regenerative therapies to repair tissue damage and restore function after spinal cord injury."
"These new findings advance our understanding of the molecular mechanisms which may orchestrate the body's remarkable capacity for natural repair," said Dr. Bradbury.
"By enhancing this spontaneous response, we may be able to significantly improve spinal cord function after injury. Our research also has wider implications for other disorders of the central nervous system which share this demyelinating pathology, such as multiple sclerosis."
Related Links:
King's College London
University of Oxford
Latest BioResearch News
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
- Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
- Study Links Abnormal Gene Splicing to Treatment Response in Metastatic Kidney Cancer
- Research Reveals How Some Aplastic Anemia Patients Recover Bone Marrow Function
- New Molecular Insights Support Diagnosis of Hodgkin Lymphoma
- Epigenetic Signals and Blood Markers Aid Chronic Fatigue Syndrome Diagnosis
- Microenvironment Biomarkers Could Enable Early Lung Cancer Detection
- Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
- Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
- Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
- Single-Cell Method Measures RNA and Proteins to Reveal Immune Responses
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
- International Consensus Standardizes Tumor Microbiota Detection and Reporting
- Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
- Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Obtaining tumor tissue can be difficult, and standard genome and RNA... Read more
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








